SEIKAGAKU Corporation · BLA 761393
ADMINISTRATION ¢ YN U.S. FOOD & DRUG BLA 761393 COMPLETE RESPONSE SEIKAGAKU Corporation c/o PAREXEL International 2520 Meridian Parkway, Suite 100 Durham, NC 27713 Attention: Katherine Fertal US Agen…
- Letter date
- 09/09/2026
- File name
- CRL_BLA761393_20260909.pdf
- Letter year
- 2026
- Approval status
- Unapproved
- Approver name
- Center for Drug Evaluation and Research
- Company rep
- Katherine Fertal
- Company address
- 2520 Meridian Parkway, Suite 100 Durham, NC 27713
- Company name
- SEIKAGAKU Corporation
- Letter type
- COMPLETE RESPONSE
- Text
ADMINISTRATION ¢ YN U.S. FOOD & DRUG BLA 761393 COMPLETE RESPONSE SEIKAGAKU Corporation c/o PAREXEL International 2520 Meridian Parkway, Suite 100 Durham, NC 27713 Attention: Katherine Fertal US Agent Dear Katherine Fertal: Please refer to your biologics license application (BLA) dated and received on March 11, 2024, and your amendments, submitted under oe for SI-6603 (condoliase) injection. We acknowledge receipt of your amendment dated March 9, 2026, which constituted a complete response to our March 11, 2025, action letter. We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues. FACILITY INSPECTIONS oa FDA reviewed the facility's response to the Post-Application Action Letter (PAAL), which FDA issued on March 18, 2025. FDA requested additional information (Requests for Additional Information - RAI) on May 27, 2026 (RAI #1) and August 3, 2026 (RAI #2). The facility provided responses to RAI #1 on June 3, 2026, and to RAI #2 on August 10, 2026. Following review of these responses, FDA has determined that facility deficiencies remain unresolved. Your complete response should include the date(s) of the facility’s correspondence(s) to address these deficiencies. FDA may need to perform an onsite pre-license inspection (PLI) before this application may be approved. Please be aware that we will not initiate the PLI until your complete response is received, and we recommend that you work with the facility, as appropriate, to resolve the facility-related deficiencies and ensure the facility is ready for a PLI. 1) As part of the facility evaluation of Reference ID: 5866184 BLA 761393 Page 2 2) Following a current good manufacturing practice (CGMP) inspection of (7° , listed in this application, FDA conveyed deficiencies to the representative of the facility. The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA 483 prior to your complete response. The facility’s satisfactory responses are dependent on FDA’s determination that the facility has come into compliance with CGMP and may require re-inspection of the facility. The deficiencies identified during the inspection may not be specific to your application. Therefore, you should coordinate with the facility for timely resolution. Your complete response should include the date(s) of the facility’s response(s) to the FDA Form 483. Please refer to Compliance Program CP 7356.002 for guidance on post inspection activities. Following resolution of the CGMP inspection, FDA may need to conduct a Pre-license inspection (PLI) of the facility. Satisfactory outcomes of both the PLI and the CGMP surveillance inspections will be needed prior to an approval of the application. PRESCRIBING INFORMATION We reserve comment on the proposed labeling until the application is otherwise adequate. In particular, your proposed changes to sections 5 and 6 remain under review, and have not been finalized, and we may have additional comments upon resubmission. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources! and Pregnancy and Lactation Labeling Final Rule? websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI), a checklist of important format items from labeling regulations and guidances. PROPRIETARY NAME Please refer to our correspondence dated May 20, 2026, which addresses the proposed proprietary name, {9}. This name was found conditionally acceptable pending approval of the application in the current review cycle. Resubmit the proposed proprietary name when you respond to all of the application deficiencies that have been identified in this letter. CARTON AND CONTAINER LABELING We reserve comment on the proposed labeling until the application is otherwise adequate. 1 https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources 2 https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs- final-rule U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5866184 BLA 761393 Page 3 SAFETY UPDATE When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level. (1) Describe in detail any significant changes or findings in the safety profile. (2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows: e Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission. e Present tabulations of the new safety data combined with the original application data. e Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above. e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in Clinical trials. (3) Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified. (4) Provide case report forms and narrative summaries for each subject who died during a Clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events. (5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data. (6) Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time). (7) Provide a summary of worldwide experience on the safety of this product. Include an updated estimate of use for product marketed in other countries. (8) Provide English translations of current approved foreign labeling not previously submitted. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5866184 BLA 761393 Page 4 ADDITIONAL COMMENTS We have the following comments/recommendations that are not approvability issues: Product Quality Drug Substance 1. Product Quality Microbiology 2. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5866184 BLA 761393 Page 5 Clinical Due to the risks of hypersensitivity and severe skin reactions, if approved, this Application warrants Enhanced Pharmacovigilance. See below for additional details. 4. We request that for you submit and investigate all serious cases of hypersensitivity reactions, including severe cutaneous adverse reactions (SCARs), (i.e., Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption) — whether domestic or foreign — as though they were 15-day “Alert reports” (which are described under 21 CFR 600.80(c)(1)) through the 5th year following the initial U.S. approval date. When you receive new information about a report of a serious hypersensitivity reaction, including SCARs, that has been previously reported, we request that you submit a follow-up individual case safety report (ICSR) containing the new information and using the same unique case identification number as the initial report (as described in 21 CFR 600.80(f)(5)(viii)). U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5866184 BLA 761393 Page 6 5. We request that you provide a narrative summary including analyses of serious hypersensitivity reactions, including SCARs, as part of your required periodic safety reports [e.g., periodic adverse experience report (PAER) required under 21 CFR 600.80(c)(2)], quarterly during the first 3 years post-approval and annually thereafter, through the 5th year following initial U.S. approval date. Your analyses should include interval and cumulative data relative to the date of approval of [I] and include cases from your global safety database, including clinical trials. Your analysis should include line listings of the cases, in addition to your summary. The summary should include three analyses: one covering all cases combined, one covering domestic cases only, and one covering foreign cases only. Your analyses should provide an assessment of causality, with documentation of indication, temporal association, duration of therapy, associated signs and symptoms, confounders, medical history, concomitant medications, underlying risk factors, treatment given for the event, outcome, and dechallenge/rechallenge. OTHER Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 601.3(b). If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 601.3(c). You may also request an extension of time in which to resubmit the application. A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle. You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry, Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products. The product may not be legally marketed until you have been notified in writing that this application is approved. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5866184 BLA 761393 Page 7 Sincerely, {See appended electronic signature page} Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5866184 Signature Page 1 of 1 This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. (b) (4) 09/09/2026 03:12:13 PM Reference ID: 5866184
- Application number
- BLA 761393
